Clinical trials

#Cell therapy #Clinical trials #Gene therapy #Oncology #Preclinical

Collaboration to investigate IMM-101 in difficult to treat cancers

This will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma. Immodulon, an immuno-oncology company, and the Champalimaud Foundation, a private, non-profit, research organisation in Lisbon, Portugal, have announced… Read More

#Cancer Research #News

#Clinical trials #Drug development #Therapeutics

Parkinson’s UK backs NRG Therapeutics’ breakthrough drug development

Parkinson’s UK has invested an additional £1 million in NRG Therapeutics mitochondrial drug development programme. This funding boost, on top of an initial £1 million investment, will support the development of a breakthrough drug with the potential to slow or halt the progression of Parkinson’s – something no… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Just-Evotec Biologics to make monoclonal antibody products for COVID-19

Image: Ani Kolleshi The US Department of Defence (DOD) has awarded Evotec’s Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19 Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Oncology #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Merging two immunotherapies may be more effective treatment against some cancers

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More

#Cancer Research #News

#Analysis #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #High throughput screening #Imaging #Mass spectrometry / NMR #Microbiology #Screening #System biology #Target validation

Avacta updates on clinical validation of Adeptrix COVID-19 diagnostic test

Image: Pille-Riin Priske Avacta has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (BAMS) laboratory assay developed with Adeptrix. The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Business #Clinical trials #Computational chemistry #Drug development

Cytel makes access to clinical trial designs easier

24 July 2020 Image: Joshua Sortino Cytel’s East Alloy platform is a web-native extension of the company’s East software for adaptive clinical trial design and analysis. By leveraging the speed of cloud computing and the pace of SaaS delivery, East Alloy enables easy implementation of computationally intensive Bayesian… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical specialities #Clinical trials #Drug discovery #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Protein chemistry / Proteomics #Therapeutics

PerkinElmer launches virtual open access Covid-19 Data Dashboards to accelerate research

The company has launched two online, free-to-access Covid-19 Data Dashboards to aid the global scientific community accelerate the discovery of antivirals and vaccines. The informatics tools are set to help scientists access, aggregate and analyse drug compound and clinical trial data and are powered by PerkinElmer’s data analytics… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Precision medicine #RNA #Therapeutics

Over £100m UK cash boost to produce millions of doses of COVID-19 vaccine

The UK’s capability to manufacture vaccines has received a substantial boost, as the UK government has announced an additional £100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the UK. The investment will fund a Cell and Gene Therapy Catapult Manufacturing Innovation… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #RNA #Stem cells

Study shows Oxford coronavirus vaccine produces strong immune response

A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Clinical trials #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

UK secures portfolio of promising vaccines candidates from BioNTech/Pfizer alliance

Millions of people could be vaccinated against coronavirus as the UK secures early access to 90 million doses of promising Covid-19 vaccine candidates. The UK government has agreed significant partnerships with leading pharmaceutical and vaccine companies BioNTech/Pfizer and Valneva that are developing new vaccines to protect people against… Read More

#Covid-19 #News

#Bioengineering #Clinical trials #RNA

Stanford neuroscientists target drug-associated memories to prevent relapse

17 July 2020 Removing memories associated with morphine use from the brains of mice enables Stanford researchers to prevent relapse and could point to a new approach for treating the opioid epidemic. By Lara Streiff Research surrounding addiction often assumes reward is the primary motivation for drug use… Read More

#News

#Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Lead discovery #Regulatory

Phase 1 clinical trial of COVID-19 vaccine begins at University of Queensland

The next critical phase for The University of Queensland’s (UQ) COVID-19 vaccine is underway, with the research effort moving out of the lab and into human trials. Healthy adult volunteers have received the first dose of the vaccine at the Brisbane clinic of phase 1 clinical trials specialist,… Read More

#Covid-19 #News

#Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug discovery #Gene therapy #Imaging #PCR #RNA

LGC expands SARS-CoV-2 molecular solutions to full genome coverage

Image: Fusion Medical Automation Initially designed to target the published CDC and WHO consensus sequences, the AccuPlex SARS-CoV-2 Verification Panel and Reference Material Kit are available with full SARS-CoV-2 viral genome coverage. This expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining the safety features and… Read More

#Covid-19 #News

#Academic #Analysis #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #Pharmacology #Screening #System biology #Systems biology #Therapeutics

Remotely accessible assays help researchers work from home

Scientists in academic centres and companies around the world desperately search for novel therapeutics and vaccines to treat and prevent COVID-19. However, with lockdowns and limited access to laboratories, researchers are being forced to work from home, putting research continuity at risk. To help scientists continue their R&D,… Read More

#Covid-19 #News

#Business #Cellular & Molecular biology #Clinical trials #Drug discovery #Imaging #Immunology #Lead discovery #Screening #Stem cells #System biology

Llama antibodies may neutralise COVID-19, study finds

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers have found. The team involves researchers from the Rosalind Franklin Institute, Oxford University, Diamond Light Source and Public Health England. They hope the antibodies – known as nanobodies due to their… Read More

#Covid-19 #News

#Academic #Biochemistry #Biomarkers #Cellular & Molecular biology #Clinical trials #Drug discovery #Drug targets #Genetics / genomes #Lead discovery #Molecular medicine #RNA #Therapeutics

New drug could treat blood cancer and solid tumours

13 July 2020 Image: National Cancer Institute Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumours. The drug, fadraciclib, was jointly discovered by scientists at The Institute… Read More

#News